{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:42Z","timestamp":1785168282365,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":700,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Rheum Dis"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1111\/1756-185x.12154","type":"journal-article","created":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T09:44:11Z","timestamp":1382780651000},"page":"527-531","source":"Crossref","is-referenced-by-count":88,"title":["Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs"],"prefix":"10.1111","volume":"16","author":[{"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Rheumatology; Department of Internal Medicine; Korea University College of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[{"name":"Division of Rheumatology; Department of Internal Medicine; The Hospital for Rheumatic Diseases; Hanyang University Medical Center; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Rheumatology; Department of Internal Medicine; Korea University College of Medicine; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,26]]},"reference":[{"key":"10.1111\/1756-185X.12154-BIB0001|apl12154-cit-0001","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/1756-185X.12154-BIB0002|apl12154-cit-0002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/1756-185X.12154-BIB0003|apl12154-cit-0003","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection-natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.12154-BIB0004|apl12154-cit-0004","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/1756-185X.12154-BIB0005|apl12154-cit-0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1111\/1756-185X.12154-BIB0006|apl12154-cit-0006","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1111\/1756-185X.12154-BIB0007|apl12154-cit-0007","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-012-1960-1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases","volume":"31","author":"Ryu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1111\/1756-185X.12154-BIB0008|apl12154-cit-0008","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1111\/1756-185X.12154-BIB0009|apl12154-cit-0009","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheumatic Dis"},{"key":"10.1111\/1756-185X.12154-BIB0010|apl12154-cit-0010","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy","volume":"36","author":"Chung","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.12154-BIB0011|apl12154-cit-0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-009-1149-4","article-title":"Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients","volume":"28","author":"Li","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1111\/1756-185X.12154-BIB0012|apl12154-cit-0012","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology"},{"key":"10.1111\/1756-185X.12154-BIB0013|apl12154-cit-0013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan","volume":"39","author":"Cho","year":"2012","journal-title":"J Dermatol"},{"key":"10.1111\/1756-185X.12154-BIB0014|apl12154-cit-0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.47102\/annals-acadmedsg.V36N2p100","article-title":"Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases","volume":"36","author":"Thong","year":"2007","journal-title":"Ann Acad Med Singapore"},{"key":"10.1111\/1756-185X.12154-BIB0015|apl12154-cit-0015","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/1756-185X.12154-BIB0016|apl12154-cit-0016","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/rheumatology\/kep003","article-title":"Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection","volume":"48","author":"Robinson","year":"2009","journal-title":"Rheumatology"},{"key":"10.1111\/1756-185X.12154-BIB0017|apl12154-cit-0017","first-page":"645","article-title":"Tumour necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/1756-185X.12154-BIB0018|apl12154-cit-0018","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jtm.12026","article-title":"Hepatitis B and C infection in international travelers","volume":"20","author":"Johnson","year":"2013","journal-title":"J Travel Med"},{"key":"10.1111\/1756-185X.12154-BIB0019|apl12154-cit-0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine"},{"key":"10.1111\/1756-185X.12154-BIB0020|apl12154-cit-0020","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1111\/1756-185X.12154-BIB0021|apl12154-cit-0021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2249.1999.00812.x","article-title":"HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines","volume":"115","author":"Schlaak","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/1756-185X.12154-BIB0022|apl12154-cit-0022","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12154-BIB0023|apl12154-cit-0023","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12154","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/1756-185X.12154\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T23:04:43Z","timestamp":1716073483000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12154","relation":{},"ISSN":["1756-1841"],"issn-type":[{"value":"1756-1841","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}